123 related articles for article (PubMed ID: 17925558)
1. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
Bomgaars LR; Bernstein M; Krailo M; Kadota R; Das S; Chen Z; Adamson PC; Blaney SM
J Clin Oncol; 2007 Oct; 25(29):4622-7. PubMed ID: 17925558
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
Vassal G; Doz F; Frappaz D; Imadalou K; Sicard E; Santos A; O'Quigley J; Germa C; Risse ML; Mignard D; Pein F
J Clin Oncol; 2003 Oct; 21(20):3844-52. PubMed ID: 14551303
[TBL] [Abstract][Full Text] [Related]
3. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Blaney S; Berg SL; Pratt C; Weitman S; Sullivan J; Luchtman-Jones L; Bernstein M
Clin Cancer Res; 2001 Jan; 7(1):32-7. PubMed ID: 11205914
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Vassal G; Couanet D; Stockdale E; Geoffray A; Geoerger B; Orbach D; Pichon F; Gentet JC; Picton S; Bergeron C; Cisar L; Assadourian S; Morland B; ;
J Clin Oncol; 2007 Feb; 25(4):356-61. PubMed ID: 17264330
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
8. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Zsíros J; Brugières L; Brock P; Roebuck D; Maibach R; Child M; Morland B; Casanova M; Pariente D; Paris C; de Camargo B; Ronghe M; Zimmermann A; Plaschkes J; Czauderna P; Perilongo G
Eur J Cancer; 2012 Dec; 48(18):3456-64. PubMed ID: 22835780
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Fouladi M; Nicholson HS; Zhou T; Laningham F; Helton KJ; Holmes E; Cohen K; Speights RA; Wright J; Pollack IF;
Cancer; 2007 Dec; 110(11):2535-41. PubMed ID: 17932894
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Clarke JL; Molinaro AM; Cabrera JR; DeSilva AA; Rabbitt JE; Prey J; Drummond DC; Kim J; Noble C; Fitzgerald JB; Chang SM; Butowski NA; Taylor JW; Park JW; Prados MD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):603-610. PubMed ID: 28233053
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
14. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Furman WL; Crews KR; Billups C; Wu J; Gajjar AJ; Daw NC; Patrick CC; Rodriguez-Galindo C; Stewart CF; Dome JS; Panetta JC; Houghton PJ; Santana VM
J Clin Oncol; 2006 Feb; 24(4):563-70. PubMed ID: 16446328
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Innocenti F; Ratain MJ
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
18. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Hernández-Marqués C; Lassaletta-Atienza A; Ruiz Hernández A; Blumenfeld Olivares JA; Arce Abaitua B; Cormenzana Carpio M; Madero Lopez L
An Pediatr (Barc); 2013 Aug; 79(2):68-74. PubMed ID: 23332825
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Daw NC; Furman WL; Stewart CF; Iacono LC; Krailo M; Bernstein ML; Dancey JE; Speights RA; Blaney SM; Croop JM; Reaman GH; Adamson PC;
J Clin Oncol; 2005 Sep; 23(25):6172-80. PubMed ID: 16135484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
